In this study, we evaluate the clinical outcomes of SGLT2 inhibitors compared with DPP4 inhibitors in patients with type 2 diabetes and AF in a nationwide population-based cohort. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.